公开(公告)号：US20140066456A1

公开(公告)日：2014-03-06

申请号：US14073030

申请日：2013-11-06

申请人： Joanne VAN RYN ,  Pilar GARIN-CHESA ,  Flavio SOLCA

发明人： Joanne VAN RYN ,  Pilar GARIN-CHESA ,  Flavio SOLCA

IPC分类号： A61K31/517 ,  A61K31/496 ,  A61K31/4439

CPC分类号： A61K31/517 ,  A61K31/4439 ,  A61K31/496 ,  A61K2300/00

摘要： The invention relates to new methods for the treatment of oncological and fibrotic diseases comprising the combined administration of a receptor tyrosine kinase inhibitor in conjunction with a thrombin inhibitor.

摘要翻译： 本发明涉及治疗肿瘤和纤维化疾病的新方法，其包括与凝血酶抑制剂联合施用受体酪氨酸激酶抑制剂。

公开(公告)号：US20140187563A1

公开(公告)日：2014-07-03

申请号：US14198726

申请日：2014-03-06

申请人： Joanne VAN RYN ,  Frank HILBERG ,  Pilar GARIN-CHESA

发明人： Joanne VAN RYN ,  Frank HILBERG ,  Pilar GARIN-CHESA

IPC分类号： A61K31/496 ,  A61K31/517 ,  A61K31/4439

CPC分类号： A61K31/496 ,  A61K31/405 ,  A61K31/4439 ,  A61K31/517 ,  A61K2300/00

摘要： The invention relates to new methods for the treatment of oncological and fibrotic disease comprising the combined administration of an inhibitor of vascular endothelial growth factor receptors (VEGFRs) in conjunction with a thrombin inhibitor.

摘要翻译： 本发明涉及用于治疗肿瘤和纤维化疾病的新方法，其包括与凝血酶抑制剂联合施用血管内皮生长因子受体（VEGFR）的抑制剂。

公开(公告)号：US20120244141A1

公开(公告)日：2012-09-27

申请号：US13237833

申请日：2011-09-20

申请人： Guenther ADOLF ,  Pilar GARIN-CHESA ,  Ulrich HIRT

发明人： Guenther ADOLF ,  Pilar GARIN-CHESA ,  Ulrich HIRT

IPC分类号： A61K39/395 ,  A61P35/00 ,  A61K31/713 ,  A61K31/7105 ,  G01N21/76 ,  G01N33/574

CPC分类号： G01N33/57492 ,  C12Q1/6886 ,  G01N33/57484 ,  G01N33/57496 ,  G01N2333/705 ,  G01N2333/91205 ,  G01N2800/52

摘要： A method for determining whether a cancer patient is susceptible to treatment with a protein tyrosine kinase 2 (PTK2) inhibitor, comprising detecting the expression of the E-cadherin protein in a cancer sample of said cancer patient, wherein an E-cadherin protein immunoreactivity score (IRS) of 0-2 indicates that the cancer patient is susceptible to treatment with a PTK2 inhibitor. The invention further encompasses treatment of a patient with a protein tyrosine kinase 2 (PTK2) inhibitor if it has been so determined that said patient is susceptible to such treatment.

摘要翻译： 一种确定癌症患者是否易于用蛋白酪氨酸激酶2（PTK2）抑制剂治疗的方法，包括检测所述癌症患者的癌症样品中E-钙粘蛋白蛋白的表达，其中E-钙粘蛋白蛋白免疫反应性评分 （IRS）为0-2表示癌症患者易于用PTK2抑制剂治疗。 如果已经确定所述患者易于进行这种治疗，本发明还包括治疗患有蛋白酪氨酸激酶2（PTK2）抑制剂的患者。

公开(公告)号：US20140205592A1

公开(公告)日：2014-07-24

申请号：US14221370

申请日：2014-03-21

申请人： Guenther ADOLF ,  Pilar GARIN-CHESA ,  Ulrich HIRT

发明人： Guenther ADOLF ,  Pilar GARIN-CHESA ,  Ulrich HIRT

IPC分类号： G01N33/574 ,  C12Q1/68

CPC分类号： G01N33/57492 ,  C12Q1/6886 ,  G01N33/57484 ,  G01N33/57496 ,  G01N2333/705 ,  G01N2333/91205 ,  G01N2800/52

摘要： The present invention relates to a method for determining whether a cancer patient is susceptible to treatment with a protein tyrosine kinase 2 (PTK2) inhibitor, comprising detecting the expression of the E-cadherin protein in a cancer sample of said cancer patient, wherein an E-cadherin protein immunoreactivity score (IRS) of 0-2 indicates that the cancer patient is susceptible to treatment with a PTK2 inhibitor. Said detection of the expression of the E-cadherin protein in a cancer sample of a cancer patient is preferably conducted by way of an immunohistochemistry (IHC) method. Said IHC method preferably employs a primary antibody which is specific for E-cadherin and a secondary antibody which specifically reacts with the primary antibody. The present invention also relates to a method of treating a cancer patient whose cancer is characterized by an E-cadherin protein immunoreactivity score (IRS) of 0-2, comprising administering to the patient a therapeutically effective amount of a PTK2 inhibitor. In a further aspect, the present invention relates to a PTK2 inhibitor for use in the treatment of a cancer patient whose cancer is characterized by an E-cadherin protein immunoreactivity score (IRS) of 0-2. The present invention also provides a method of screening for a therapeutically effective PTK2 inhibitor comprising the steps of (a) providing cancer cells or a cancer cell line which are characterized by an E-cadherin protein immunoreactivity score of 2, 1, or 0 (1 being preferred and 0 being even more preferred); (b) contacting the cancer cell or the cancer cell line of (a) with a PTK2 inhibitor; and (c) evaluating whether the PTK2 inhibitor negatively affects the cancer cell/cancer cell lines. In a further aspect, the present invention relates to a method for stratifying cancer patients that are susceptible to treatment with a PTK2 inhibitor, comprising determining the E-cadherin IRS score in a cancer sample of said patient, wherein an E-cadherin protein immunoreactivity score (IRS) of 0-2 (i.e. 2, 1, or 0) indicates that the cancer patient is susceptible to treatment with a PTK2 inhibitor. The present invention also relates to a pharmaceutical package comprising a PTK2 inhibitor, and (a) instructions and/or an imprint indicating that said PTK2 inhibitor is to be used for the treatment of patients which suffer from a cancer which is characterized by an E-cadherin protein immunoreactivity score of 2, 1, or 0 (1 being preferred and 0 being more preferred); and/or (b) instructions and/or an imprint indicating that said patient is to be stratified by a method of the present invention; and/or (c) means to carry out a method as defined herein.